Illumina Inc. (ILMN) is highlighted as one of the top oncology stocks to buy now, with TD Cowen raising its price target to $140 from $115. The company recently launched Illumina Connected Multiomics, a cloud-based platform for analyzing large multiomic datasets. Illumina is a leader in oncology-focused genomic innovation.

Despite the potential of Illumina Inc. (ILMN) as an investment, some AI stocks may offer greater upside potential with less downside risk. For those seeking undervalued AI stocks, a free report on the best short-term AI stock is available. Illumina’s advanced genomic sequencing and multiomics solutions position them as a key player in oncology research and personalized treatment strategies.

Read more at Yahoo Finance: Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside